{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:31:14Z","timestamp":1791419474204,"version":"4.3.3"},"reference-count":201,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be a manifestation of various combinations of cardiovascular, metabolic, pulmonary, renal, and geriatric conditions. Thus, in addition to treatment with sodium\u2013glucose cotransporter 2 inhibitors in all patients, the most effective method of improving clinical outcomes may be therapy tailored to each patient's clinical profile. To better outline a phenotype-based approach for the treatment of HFpEF, in this joint position paper, the Heart Failure Association of the European Society of Cardiology, the European Heart Rhythm Association and the European Hypertension Society, have developed an algorithm to identify the most common HFpEF phenotypes and identify the evidence-based treatment strategy for each, while taking into account the complexities of multiple comorbidities and polypharmacy.<\/jats:p>","DOI":"10.1002\/ejhf.2894","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:24:04Z","timestamp":1684470244000},"page":"936-955","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":192,"title":["Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension"],"prefix":"10.1093","volume":"25","author":[{"given":"Stefan D.","family":"Anker","sequence":"first","affiliation":[{"name":"Department of Cardiology, Deutsches Herzzentrum der Charit\u00e9 (Campus CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT), and German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shariq","family":"Usman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center , Jackson, MS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus S.","family":"Anker","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9, Klinik f\u00e4r Kardiologie, Angiologie und Intensivmedizin (Campus CBF), Berlin Institute of Health Center for Regenerative Therapies (BCRT), and German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center , Jackson, MS ,","place":["USA"]},{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Abraham","sequence":"additional","affiliation":[{"name":"Ohio State University Wexner Medical Center , Columbus, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Chopra","sequence":"additional","affiliation":[{"name":"Max Superspeciality Hospital , New Delhi ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariantonietta","family":"Cicoira","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Magalini Hospital , Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cosentino","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, School of Medicine , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa A.","family":"Jankowska","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroclaw Medical University , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Moura","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o em Tecnologias e Servi\u00e7os de Sa\u00fade, Porto, Portugal; Servi\u00e7o de Cardiologia, Hospital das For\u00e7as Armadas-P\u00f3lo do Porto , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Mullens","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost Limburg, Genk and Faculty of Medicine and Life Sciences , University Hasselt ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkert","family":"Pieske","sequence":"additional","affiliation":[{"name":"Berlin-Brandenburgische Gesellschaft f\u00fcr Herz-Kreislauferkrankungen (BBGK), Berlin \u00a0","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroclaw Medical University , Wroclaw ,","place":["Poland"]},{"name":"Cardiology Department, Wroclaw Medical University , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R.","family":"Gonzalez-Juanatey","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario, Santiago de Compostela, IDIS, CIBERCV , Santiago de Compostela ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Rakisheva","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Scientific Institution of Cardiology and Internal Diseases , Almaty ,","place":["Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Seferovic","sequence":"additional","affiliation":[{"name":"Department Faculty of Medicine, University of Belgrade, Belgrade & Serbian Academy of Sciences and Arts , Belgrade ,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Teerlink","sequence":"additional","affiliation":[{"name":"Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Tsch\u00f6pe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Deutsches Herzzentrum der Charit\u00e9 (Campus CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT), and German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]},{"name":"Department of Cardiology, Angiology and Intensive Care Medicine (CVK), Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Volterrani","sequence":"additional","affiliation":[{"name":"Cardio-Pulmonary Department, San Raffaele Open University of Rome; Exercise Science and Medicine, IRCCS San Raffaele \u2013 Rome \u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medcine G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fuwai Hospital Chinese Academic of Medical Science , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fuwai Hospital Chinese Academic of Medical Science , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9, Klinik f\u00e4r Kardiologie, Angiologie und Intensivmedizin (Campus CBF), Berlin Institute of Health Center for Regenerative Therapies (BCRT), and German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]},{"name":"Berlin Institute of Health at Charit\u00e9 , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Max Rady College of Medicine, University of Manitoba Winnipeg , Winnipeg, Manitoba ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[{"name":"Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, CIBERCV , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u2018Prof. C.C. Iliescu\u2019, University of Medicine Carol Davila , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicita","family":"Andreotti","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Gemelli IRCCS , Rome ,","place":["Italy"]},{"name":"Catholic University Medical School , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Agabiti-Rosei","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Merino","sequence":"additional","affiliation":[{"name":"Department of Cardiology, La Paz University Hospital, IdiPaz, Universidad Autonoma , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.S.","family":"Coats","sequence":"additional","affiliation":[{"name":"Heart Research Institute , Newtown, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe M.C.","family":"Rosano","sequence":"additional","affiliation":[{"name":"Cardio-Pulmonary Department, San Raffaele Open University of Rome; Exercise Science and Medicine, IRCCS San Raffaele \u2013 Rome \u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"2026080801314700600_ejhf2894-bib-0001","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"key":"2026080801314700600_ejhf2894-bib-0002","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0003","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","article-title":"Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review","volume":"73","author":"McHugh","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0004","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: A review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"2026080801314700600_ejhf2894-bib-0005","first-page":"768","article-title":"Drug development for heart failure with preserved ejection fraction: What pieces are missing from the puzzle?","volume":"33","author":"Senni","year":"2017","journal-title":"Can J Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0006","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0007","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0009","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0010","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial","volume":"10","author":"Solomon","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0011","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026080801314700600_ejhf2894-bib-0012","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0013","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0014","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT \u2013 new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0015","volume-title":"Spironolactone in the Treatment of Heart Failure (SPIRIT-HF)","author":"ClinicalTrials.gov"},{"key":"2026080801314700600_ejhf2894-bib-0016","volume-title":"Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction (SPIRRIT)","author":"ClinicalTrials.gov"},{"key":"2026080801314700600_ejhf2894-bib-0017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0018","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCHEARTFAILURE.114.001615","article-title":"Exercise training in patients with heart failure and preserved ejection fraction: Meta-analysis of randomized control trials","volume":"8","author":"Pandey","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0019","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.hjc.2021.10.003","article-title":"Effects of different exercise programs on the cardiorespiratory reserve in HFpEF patients: A systematic review and meta-analysis","volume":"64","author":"Boulmpou","year":"2022","journal-title":"Hellenic J Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0020","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jacc.2016.11.081","article-title":"Relationship between physical activity, body mass index, and risk of heart failure","volume":"69","author":"Pandey","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0021","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0022","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/FJC.0000000000001254","article-title":"Physical exercise modalities for the management of heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"79","author":"Guo","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026080801314700600_ejhf2894-bib-0023","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.2020.26812","article-title":"OptimEx-Clin Study Group. Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"325","author":"Mueller","year":"2021","journal-title":"JAMA"},{"key":"2026080801314700600_ejhf2894-bib-0024","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jacc.2019.05.052","article-title":"Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction","volume":"74","author":"Tromp","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12967-021-02935-x","article-title":"Heart failure with preserved ejection fraction based on aging and comorbidities","volume":"19","author":"Lin","year":"2021","journal-title":"J Transl Med"},{"issue":"1","key":"2026080801314700600_ejhf2894-bib-0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2022.04.040","article-title":"Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age","volume":"80","author":"B\u00f6hm","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0027","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10741-019-09824-y","article-title":"Gender-related differences in heart failure: Beyond the \u201cone-size-fits-all\u201d paradigm","volume":"25","author":"De Bellis","year":"2020","journal-title":"Heart Fail Rev"},{"key":"2026080801314700600_ejhf2894-bib-0028","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/CIRCULATIONAHA.118.034271","article-title":"Sex differences in cardiovascular pathophysiology: Why women are overrepresented in heart failure with preserved ejection fraction","volume":"138","author":"Beale","year":"2018","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0029","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00392-011-0305-4","article-title":"Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction","volume":"100","author":"Edelmann","year":"2011","journal-title":"Clin Res Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0030","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jchf.2019.03.011","article-title":"Sex-based differences in heart failure across the ejection fraction spectrum: Phenotyping, and prognostic and therapeutic implication","volume":"7","author":"Stolfo","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0031","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.122.059755","article-title":"Effects of empagliflozin in women and men with heart failure and preserved ejection fraction","volume":"146","author":"Butler","year":"2022","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0032","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.122.062832","article-title":"Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: Insights from DAPA-HF and DELIVER","volume":"147","author":"Wang","year":"2023","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0033","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: Insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0034","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0035","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"2026080801314700600_ejhf2894-bib-0036","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.116.024593","article-title":"Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)","volume":"135","author":"Kristensen","year":"2017","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0037","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0038","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10557-017-6754-x","article-title":"Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes","volume":"31","author":"Kristensen","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026080801314700600_ejhf2894-bib-0039","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2016.07.025","article-title":"Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry","volume":"182","author":"Echouffo-Tcheugui","year":"2016","journal-title":"Am Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0041","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007901","article-title":"Global differences in heart failure with preserved ejection fraction: The PARAGON-HF trial","volume":"14","author":"Tromp","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0042","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jchf.2016.09.015","article-title":"Prevalence and clinical significance of diabetes in Asian versus white patients with heart failure","volume":"5","author":"Bank","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0043","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovi\u0107","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0044","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1210\/jc.2007-1817","article-title":"The role of advanced glycation end products in progression and complications of diabetes","volume":"93","author":"Goh","year":"2008","journal-title":"J Clin Endocrinol Metabol"},{"key":"2026080801314700600_ejhf2894-bib-0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4330\/wjc.v4.i4.90","article-title":"Role of advanced glycation end products in cardiovascular disease","volume":"4","author":"Hegab","year":"2012","journal-title":"World J Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0046","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1479164115580936","article-title":"Metabolic abnormalities of the heart in type II diabetes","volume":"12","author":"Amaral","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"2026080801314700600_ejhf2894-bib-0047","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000433","article-title":"Taking diabetes to heart \u2013 deregulation of myocardial lipid metabolism in diabetic cardiomyopathy","volume":"2","author":"Bayeva","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026080801314700600_ejhf2894-bib-0048","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCULATIONAHA.106.645614","article-title":"Cardiac steatosis in diabetes mellitus: A 1H-magnetic resonance spectroscopy study","volume":"116","author":"McGavock","year":"2007","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0049","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/01.RES.0000207406.94146.c2","article-title":"Diabetic cardiomyopathy: The search for a unifying hypothesis","volume":"98","author":"Poornima","year":"2006","journal-title":"Circ Res"},{"key":"2026080801314700600_ejhf2894-bib-0050","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jacc.2005.09.030","article-title":"Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus","volume":"47","author":"Herrero","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0051","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.yjmcc.2010.02.012","article-title":"Insulin signaling regulates cardiac titin properties in heart development and diabetic cardiomyopathy","volume":"48","author":"Kr\u00fcger","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0052","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11154-010-9134-4","article-title":"Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications","volume":"11","author":"Tabit","year":"2010","journal-title":"Rev Endocrine Metabolic Disord"},{"key":"2026080801314700600_ejhf2894-bib-0053","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0054","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0055","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0056","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0057","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0058","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0059","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0061","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0062","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/ejhf.2026","article-title":"Heart Failure Association of the European Society of Cardiology update on sodium\u2013glucose co-transporter 2 inhibitors in heart failure","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0063","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.004396","article-title":"Association of central adiposity with adverse cardiac mechanics: Findings from the Hypertension Genetic Epidemiology Network study","volume":"9","author":"Selvaraj","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080801314700600_ejhf2894-bib-0064","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14634","article-title":"Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction","volume":"8","author":"Sarma","year":"2020","journal-title":"Physiol Rep"},{"key":"2026080801314700600_ejhf2894-bib-0065","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.mayocp.2018.11.037","article-title":"Characterization of the obese phenotype of heart failure with preserved ejection fraction: A RELAX trial ancillary study","volume":"94","author":"Reddy","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2026080801314700600_ejhf2894-bib-0066","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2174\/1570161112666140423223529","article-title":"Cardiovascular effects of current and future anti-obesity drugs","volume":"12","author":"Comerma-Steffensen","year":"2014","journal-title":"Curr Vasc Pharmacol"},{"key":"2026080801314700600_ejhf2894-bib-0067","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0068","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0069","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF03091773","article-title":"Central sleep apnoea syndrome in chronic heart failure: An underestimated and treatable comorbidity","volume":"18","author":"M\u00fcller","year":"2010","journal-title":"Neth Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0070","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJMoa1506459","article-title":"Adaptive servo-ventilation for central sleep apnea in systolic heart failure","volume":"373","author":"Cowie","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0071","volume-title":"Effect of adaptive servo ventilation (ASV) on survival and hospital admissions in heart failure (ADVENT-HF)","author":"National Institutes of Health","year":"2015"},{"key":"2026080801314700600_ejhf2894-bib-0072","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurjhf\/hfs197","article-title":"Impact of adaptive servo-ventilation on cardiovascular function and prognosis in heart failure patients with preserved left ventricular ejection fraction and sleep-disordered breathing","volume":"15","author":"Yoshihisa","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0073","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejheart.2007.12.010","article-title":"Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial","volume":"10","author":"McMurray","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0074","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","article-title":"Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0075","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1097\/HJH.0000000000002910","article-title":"Hypertension and heart failure with preserved ejection fraction: Position paper by the European Society of Hypertension","volume":"39","author":"Kasiakogias","year":"2021","journal-title":"J Hypertens"},{"key":"2026080801314700600_ejhf2894-bib-0076","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1089\/ars.2006.8.691","article-title":"NADPH oxidases in cardiovascular health and disease","volume":"8","author":"Cave","year":"2006","journal-title":"Antioxid Redox Signal"},{"key":"2026080801314700600_ejhf2894-bib-0077","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ejhf.945","article-title":"A comprehensive population-based characterization of heart failure with mid-range ejection fraction","volume":"19","author":"Koh","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0078","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijcard.2017.09.187","article-title":"Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction","volume":"254","author":"Teng","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0079","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/jch.13210","article-title":"Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension","volume":"20","author":"Gu","year":"2018","journal-title":"J Clin Hyperten (Greenwich)"},{"key":"2026080801314700600_ejhf2894-bib-0080","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80\u2009years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0081","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ajh\/hpv050","article-title":"Cardioprotective effect of thiazide-like diuretics: A meta-analysis","volume":"28","author":"Chen","year":"2015","journal-title":"Am J Hypertens"},{"key":"2026080801314700600_ejhf2894-bib-0082","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2026080801314700600_ejhf2894-bib-0083","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/HJH.0000000000000378","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J Hypertens"},{"key":"2026080801314700600_ejhf2894-bib-0084","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0085","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0086","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0087","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA Focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0088","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","article-title":"Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan","volume":"75","author":"Selvaraj","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0089","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022765","article-title":"Time in target range for systolic blood pressure and cardiovascular outcomes in patients with heart failure with preserved ejection fraction","volume":"11","author":"Huang","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026080801314700600_ejhf2894-bib-0090","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/j.amjmed.2020.08.030","article-title":"Systolic blood pressure and outcomes in older patients with HFpEF and hypertension","volume":"134","author":"Faselis","year":"2021","journal-title":"Am J Med"},{"key":"2026080801314700600_ejhf2894-bib-0091","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0092","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/HYPERTENSIONAHA.109.138529","article-title":"Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction","volume":"55","author":"Solomon","year":"2010","journal-title":"Hypertension"},{"key":"2026080801314700600_ejhf2894-bib-0093","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/eurheartj\/ehs299","article-title":"Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency","volume":"34","author":"Lam","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0094","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jchf.2017.08.015","article-title":"Reverse J-curve relationship between on-treatment blood pressure and mortality in patients with heart failure","volume":"5","author":"Lee","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0095","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jchf.2017.09.010","article-title":"Blood pressure risk associations in heart failure: True effects or inverse causality?","volume":"5","author":"B\u00f6hm","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0096","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to heart failure: Contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0097","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: A community-based study","volume":"53","author":"Lam","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0098","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","article-title":"Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction","volume":"74","author":"Shah","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0099","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0100","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jchf.2013.05.001","article-title":"Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: Pulmonary hypertension and heart failure","volume":"1","author":"Miller","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0101","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12872-020-01671-2","article-title":"Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre-and postcapillary pulmonary hypertension: A randomized open-label pilot study","volume":"20","author":"Belyavskiy","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"2026080801314700600_ejhf2894-bib-0102","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0103","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1002\/ehf2.13429","article-title":"Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction","volume":"8","author":"Gaziano","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0104","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jjcc.2019.01.005","article-title":"Prognostic impact of chronic obstructive pulmonary disease on adverse prognosis in hospitalized heart failure patients with preserved ejection fraction \u2013 a report from the JASPER registry","volume":"73","author":"Sato","year":"2019","journal-title":"J Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijcard.2018.04.001","article-title":"Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction","volume":"271","author":"Streng","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0106","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjcard.2021.03.009","article-title":"Impact of chronic obstructive pulmonary disease in heart failure with preserved ejection fraction","volume":"149","author":"Jain","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0107","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction: Detailed phenotypes, prognosis, and response to spironolactone","volume":"8","author":"Cohen","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0108","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11739-015-1319-0","article-title":"Prognostic implications of heart failure with preserved ejection fraction in patients with an exacerbation of chronic obstructive pulmonary disease","volume":"11","author":"Marcun","year":"2016","journal-title":"Intern Emerg Med"},{"key":"2026080801314700600_ejhf2894-bib-0109","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCRESAHA.118.313832","article-title":"The \u03b2-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction: A randomized controlled trial","volume":"124","author":"Reddy","year":"2019","journal-title":"Circ Res"},{"key":"2026080801314700600_ejhf2894-bib-0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ejhf.2012","article-title":"Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: Insights from the RELAX-AHF-2 study","volume":"23","author":"Feng","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0111","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1159\/000502874","article-title":"Association of chronic kidney disease with preserved ejection fraction heart failure is independent of baseline cardiac function","volume":"44","author":"Mavrakanas","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"2026080801314700600_ejhf2894-bib-0112","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.497","article-title":"Connecting heart failure with preserved ejection fraction and renal dysfunction: The role of endothelial dysfunction and inflammation","volume":"18","author":"Ter Maaten","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0113","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1093\/eurheartj\/ehu254","article-title":"Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction","volume":"35","author":"Gori","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0114","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.445","article-title":"Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction","volume":"18","author":"Unger","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0116","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003588","article-title":"Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: A meta-analysis of published study data","volume":"10","author":"Beldhuis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0117","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jacc.2020.12.057","article-title":"Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function","volume":"77","author":"Beldhuis","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0118","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ejhf.2450","article-title":"Effects of sacubitril\/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF","volume":"24","author":"Peikert","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0119","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: Analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0120","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0121","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001012","article-title":"Iron deficiency in heart failure with preserved ejection fraction: A systematic review and meta-analysis","volume":"6","author":"Beale","year":"2019","journal-title":"Open Heart"},{"key":"2026080801314700600_ejhf2894-bib-0122","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","article-title":"Criteria for iron deficiency in patients with heart failure","volume":"79","author":"Masini","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0123","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.jacc.2014.03.034","article-title":"Implications of coronary artery disease in heart failure with preserved ejection fraction","volume":"63","author":"Hwang","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0124","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1093\/eurheartj\/ehy531","article-title":"Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF","volume":"39","author":"Shah","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0125","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/jamacardio.2021.1825","article-title":"Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"6","author":"Rush","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0126","first-page":"473","article-title":"The parallel tales of microvascular angina and heart failure with preserved ejection fraction: A paradigm shift","volume":"38","author":"Crea","year":"2017","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacc.2018.04.039","article-title":"Myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction","volume":"72","author":"Obokata","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0128","doi-asserted-by":"crossref","first-page":"H1033","DOI":"10.1152\/ajpheart.00680.2017","article-title":"Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"314","author":"Dryer","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026080801314700600_ejhf2894-bib-0129","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ejhf.1671","article-title":"Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"22","author":"Yang","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0130","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0131","article-title":"Is revascularization an effective therapy for heart failure with preserved ejection fraction?","volume":"128","author":"Hwang","year":"2013","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0132","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ejhf.2446","article-title":"Revascularization in ischaemic heart failure with preserved ejection fraction: A nationwide cohort study","volume":"24","author":"Deo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0133","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0134","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.amjmed.2014.09.016","article-title":"Resting heart rate: Risk indicator and emerging risk factor in cardiovascular disease","volume":"128","author":"B\u00f6hm","year":"2015","journal-title":"Am J Med"},{"key":"2026080801314700600_ejhf2894-bib-0136","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.902","article-title":"Heart rate and its reduction in chronic heart failure and beyond","volume":"19","author":"Nikolovska Vukadinovi\u0107","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0137","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"B\u00f6hm","year":"2010","journal-title":"Lancet"},{"key":"2026080801314700600_ejhf2894-bib-0138","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2011.12.044","article-title":"Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: Results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program","volume":"59","author":"Castagno","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0139","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ejhf.85","article-title":"Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)","volume":"16","author":"B\u00f6hm","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0140","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.876","article-title":"Effect of ivabradine in patients with heart failure with preserved ejection fraction: The EDIFY randomized placebo-controlled trial","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0141","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ejhf.114","article-title":"Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT","volume":"16","author":"Komajda","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0142","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2026080801314700600_ejhf2894-bib-0143","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ejhf.22","article-title":"Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: A report from the CHART-2 study","volume":"16","author":"Takada","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0144","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/ejhf.346","article-title":"Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis","volume":"17","author":"Simpson","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0145","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ejhf.2146","article-title":"Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction","volume":"23","author":"Wolsk","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0146","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00392-020-01633-w","article-title":"Therapeutic approaches in heart failure with preserved ejection fraction: Past, present, and future","volume":"109","author":"Wintrich","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0147","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0148","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0149","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","article-title":"Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study","volume":"14","author":"Conraads","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/jamacardio.2022.5320","article-title":"Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: The myPACE randomized clinical trial","volume":"8","author":"Infeld","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0151","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/ejhf.2677","article-title":"Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial","volume":"24","author":"B\u00f6hm","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0152","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2010.03.077","article-title":"Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction","volume":"56","author":"Borlaug","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0153","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1161\/CIRCULATIONAHA.110.940577","article-title":"Chronotropic incompetence: Causes, consequences, and management","volume":"123","author":"Brubaker","year":"2011","journal-title":"Circulation"},{"key":"2026080801314700600_ejhf2894-bib-0154","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004969","article-title":"Chronotropic incompetence in chronic heart failure","volume":"11","author":"Zweerink","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0155","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ehf2.12281","article-title":"Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction","volume":"5","author":"Dom\u00ednguez","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0156","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0157","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0158","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2023.0675","article-title":"Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: The RAPID-HF randomized clinical trial","volume":"329","author":"Reddy","year":"2023","journal-title":"JAMA"},{"key":"2026080801314700600_ejhf2894-bib-0159","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.jacc.2019.02.061","article-title":"Atrial functional mitral regurgitation: JACC review topic of the week","volume":"73","author":"Deferm","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0160","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2011.06.032","article-title":"Evidence of atrial functional mitral regurgitation due to atrial fibrillation: Reversal with arrhythmia control","volume":"58","author":"Gertz","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0161","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/ejhf.562","article-title":"Functional mitral regurgitation at discharge and outcomes in patients hospitalized for acute decompensated heart failure with a preserved or reduced ejection fraction","volume":"18","author":"Kajimoto","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0162","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.010300","article-title":"Implications of atrial fibrillation on the mechanisms of mitral regurgitation and response to MitraClip in the COAPT trial","volume":"14","author":"Gertz","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"2026080801314700600_ejhf2894-bib-0163","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.echo.2017.09.010","article-title":"Clinical outcome of isolated tricuspid regurgitation in patients with preserved left ventricular ejection fraction and pulmonary hypertension","volume":"31","author":"Bar","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080801314700600_ejhf2894-bib-0164","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ehjci\/jeaa286","article-title":"Right atrial volume is a major determinant of tricuspid annulus area in functional tricuspid regurgitation: A three-dimensional echocardiographic study","volume":"22","author":"Muraru","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080801314700600_ejhf2894-bib-0165","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.amjcard.2021.09.021","article-title":"Functional tricuspid regurgitation and right atrial remodeling in heart failure with preserved ejection fraction","volume":"162","author":"Harada","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0166","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1002\/ehf2.13014","article-title":"The prevalence, predictors, and prognosis of tricuspid regurgitation in stage B and C heart failure with preserved ejection fraction","volume":"7","author":"Ren","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0167","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/ejhf.1492","article-title":"Acute heart failure congestion and perfusion status \u2013 impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry","volume":"21","author":"Chioncel","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0168","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/ejhf.1975","article-title":"Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction","volume":"22","author":"Kresoja","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0169","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ejhf.1611","article-title":"Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure","volume":"21","author":"Vitale","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jcsm.12883","article-title":"Scoring the physical frailty phenotype of patients with heart failure","volume":"13","author":"Konishi","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026080801314700600_ejhf2894-bib-0171","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/M21-4776","article-title":"Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: A post hoc analysis of the DAPA-HF trial","volume":"175","author":"Butt","year":"2022","journal-title":"Ann Intern Med"},{"key":"2026080801314700600_ejhf2894-bib-0172","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0140-6736(19)31792-1","article-title":"Identifying optimal doses of heart failure medications in men compared with women: A prospective, observational, cohort study","volume":"394","author":"Santema","year":"2019","journal-title":"Lancet"},{"key":"2026080801314700600_ejhf2894-bib-0173","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/eurheartj\/ehz550","article-title":"Routinely reported ejection fraction and mortality in clinical practice: Where does the nadir of risk lie?","volume":"41","author":"Wehner","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0174","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/eurheartj\/ehz706","article-title":"Hyperdynamic left ventricular function and the prognostic implications for heart failure with preserved ejection fraction","volume":"41","author":"Ng","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0175","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.36660\/abc.20190835","article-title":"Heart failure with supra-normal left ventricular ejection fraction \u2013 state of the art","volume":"116","author":"Huang","year":"2021","journal-title":"Arq Bras Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0176","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cardfail.2016.03.013","article-title":"Prognosis of low normal left ventricular ejection fraction in an asymptomatic population-based adult cohort: the Multiethnic Study of Atherosclerosis","volume":"22","author":"Yeboah","year":"2016","journal-title":"J Card Fail"},{"key":"2026080801314700600_ejhf2894-bib-0177","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ejhf.2047","article-title":"Ejection fraction and mortality: A nationwide register-based cohort study of 499\u2009153 women and men","volume":"23","author":"Stewart","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0178","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: The HFA\u2013PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0179","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/ejhf.2210","article-title":"Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings","volume":"23","author":"Hadzibegovic","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0180","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovi\u0107","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0181","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080801314700600_ejhf2894-bib-0183","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0184","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0185","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jcmg.2019.07.018","article-title":"Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy","volume":"13","author":"Upshaw","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080801314700600_ejhf2894-bib-0186","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CRD.0000000000000161","article-title":"Ability of nonstrain diastolic parameters to predict doxorubicin-induced cardiomyopathy: A systematic review with meta-analysis","volume":"26","author":"Nagiub","year":"2018","journal-title":"Cardiol Rev"},{"key":"2026080801314700600_ejhf2894-bib-0187","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004408","article-title":"Longitudinal assessment of vascular function with sunitinib in patients with metastatic renal cell carcinoma","volume":"11","author":"Catino","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0188","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2026080801314700600_ejhf2894-bib-0189","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: An analysis of the FDA Adverse Event Reporting System database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026080801314700600_ejhf2894-bib-0190","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0191","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2018.01.017","article-title":"Spectrum of restrictive and infiltrative cardiomyopathies: Part 2 of a 2-part series","volume":"71","author":"Pereira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0192","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.amjcard.2018.07.012","article-title":"Primary and secondary diastolic dysfunction in heart failure with preserved ejection fraction","volume":"122","author":"Del Buono","year":"2018","journal-title":"Am J Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0193","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080801314700600_ejhf2894-bib-0194","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1002\/ehf2.13360","article-title":"Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy","volume":"8","author":"Devesa","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026080801314700600_ejhf2894-bib-0195","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2019.16","article-title":"Cardiac transthyretin-derived amyloidosis: An emerging target in heart failure with preserved ejection fraction?","volume":"6","author":"Klaassen","year":"2020","journal-title":"Card Fail Rev"},{"key":"2026080801314700600_ejhf2894-bib-0196","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080801314700600_ejhf2894-bib-0197","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12916-021-02219-7","article-title":"Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy","volume":"20","author":"Liu","year":"2022","journal-title":"BMC Med"},{"key":"2026080801314700600_ejhf2894-bib-0198","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen Steve","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0199","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/CIRCIMAGING.113.001613","article-title":"Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria","volume":"7","author":"Welch","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080801314700600_ejhf2894-bib-0200","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.jacc.2016.02.070","article-title":"Paradoxical low-gradient aortic stenosis: The HFpEF of aortic stenosis","volume":"67","author":"Chin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026080801314700600_ejhf2894-bib-0201","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1016\/j.jacc.2015.09.076","article-title":"Outcome and impact of aortic valve replacement in patients with preserved LVEF and low-gradient aortic stenosis","volume":"66","author":"Dayan","year":"2015","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/7\/936\/65494426\/eurjhf_25_7_936.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/7\/936\/65494426\/eurjhf_25_7_936.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:32:24Z","timestamp":1786167144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/7\/936\/8341850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":201,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,17]]},"published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2894","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,7,1]]},"assertion":[{"value":"2023-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}